세계의 편두통 치료제 시장 : 시장 규모, 점유율 및 동향 분석
Migraine Drugs Market Size, Share & Trends Analysis Report By Treatment (Acute, Preventive), By Therapeutic Class, By Route Of Administration, By Age Group (Pediatric, Adult, Geriatric), By Availability, By Region, And Segment Forecasts, 2025 - 2030
상품코드
:
1726254
리서치사
:
Grand View Research, Inc.
발행일
:
2025년 04월
페이지 정보
:
영문 159 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
편두통 치료제 시장의 성장 및 동향 :
Grand View Research, Inc.의 최신 보고서에 따르면, 세계의 편두통 치료제 시장 규모는 2030년까지 133억 4,000만 달러에 달할 전망이며, 2025-2030년 CAGR 10.9%를 나타낼 것으로 예측되고 있습니다. 이 시장을 크게 견인하고 있는 것은 질환 유병률의 상승, 신규 치료법의 개발, 라이프 스타일의 변화, 호르몬 약 등의 요인입니다.
편두통은 3일 이상 계속되는 심하게 욱신거리는 머리의 통증의 재발 발작을 특징으로 하는 쇠약성 신경 질환입니다. 편두통의 통증은 움직이며 악화해, 환자가 통상의 일상생활을 보낼 수 없게 되는 일도 있습니다. 발작의 약 3분의 1에서는 머리, 얼굴, 목의 양쪽이 모이게 됩니다.
지난 5년간 세계의 편두통 치료제 시장은 비교적 정체되어 있어 주로 제네릭의 트립탄계 약제나 기타 적응외 약제가 시장을 독점하고 있습니다. 현재 처방되고 있는 약제의 대부분은 급성기 치료용, 예방 치료용 모두 유효성이 낮고 부작용 프로파일도 바람직하지 않습니다.
Amgen/Novartis의 CGRP mAb Aimovig와 Teva Pharma의 Ajovy 출시는 편두통 예방 치료 패러다임을 변화시키는 첫 걸음입니다. Eli Lilly사, Alder BioPharma사, Biohaven Pharma사 등 2019년까지 시장에 진입할 가능성이 있는 제약업체 입장에서는 CGRP 기반 치료제가 모두 유사한 유효성과 안전성 프로파일을 갖기 때문에 가격 책정이 차별화의 열쇠가 될 것으로 보입니다.
편두통 치료제 시장 : 분석 개요
- 치료제별로는 2024년에는 예방 부문이 62.03%의 최대 매출 점유율로 시장을 리드했습니다. 급성기 부문은 2024년에 2위의 시장 수익 점유율을 차지했습니다.
- 치료 등급별로는 CGRP 단일클론항체 부문이 2024년에 56.68%의 최대 매출 점유율로 시장을 선도했습니다. CAGR 저분자 길항제 진단제 부문은 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
- 투여 경로별로는 주사제가 2024년에 69.48%의 최대 매출 점유율로 시장을 선도했습니다. 경구제 부문은 예측 기간 중에 현저한 CAGR을 나타낼 것으로 예측되고 있습니다.
- 연령층에 의하면, 성인 부문은 2024년에 52.92%의 최대 수익 점유율로 시장을 리드했으며, 예측 기간 중에 현저한 CAGR로 성장할 것으로 예측됩니다. 노인 부문은 예측 기간 동안 CAGR에서 크게 성장할 것으로 예측됩니다.
- 입수 수단별로, 처방약 부문은 2024년에 62.38%의 최대 수익 점유율로 시장을 선도하였고, 예측 기간 중에 현저한 CAGR로 성장할 것으로 예측됩니다.
목차
제1장 분석 방법 및 범위
제2장 주요 요약
제3장 편두통 치료제 시장 : 변동 요인, 경향 및 범위
- 시장 연관 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 편두통 치료제 시장 : 분석 도구
- 업계 분석 : Porter's Five Forces 분석
- PESTEL 분석
- 가격 분석
- 파이프라인 분석 : 위상별
제4장 편두통 치료제 시장 : 치료제별 추정 및 동향 분석
- 세계의 편두통 치료제 시장 : 치료제별 대시보드
- 세계의 편두통 치료제 시장 : 치료제별 변동 분석
- 세계의 편두통 치료제 시장 : 치료제별(수익 베이스)
- 급성
- 예방
제5장 편두통 치료제 시장 : 치료 등급별 추정 및 동향 분석
- 세계의 편두통 치료제 시장 : 치료 등급별 대시보드
- 세계의 편두통 치료제 시장 : 치료 등급별 변동 분석
- 세계의 편두통 치료제 시장 : 치료 등급별(수익 베이스, )
- CGRP 단일클론항체
- CGRP 소분자 길항제
- 아세틸콜린 억제제 및 신경독
- 트립탄
- 디탄스
- 맥각 알칼로이드
- NSAID
- 기타
제6장 편두통 치료제 시장 : 투여 경로별 추정 및 동향 분석
- 세계의 편두통 치료제 시장 : 투여 경로별 대시보드
- 세계의 편두통 치료제 시장 : 투여 경로별 변동 분석
- 세계의 편두통 치료제 시장 : 투여 경로별(수익 기준)
- 경구약
- 주사약
- 기타
제7장 편두통 치료제 시장 : 연령층별 추정 및 동향 분석
- 세계의 편두통 치료제 시장 : 연령층별 대시보드
- 세계의 편두통 치료제 시장 : 연령층별 변동 분석
- 세계의 편두통 치료제 시장 : 연령층별(수익 베이스)
- 소아
- 성인
- 고령자
제8장 편두통 치료제 시장 : 입수 수단별 추정 및 동향 분석
- 세계의 편두통 치료제 시장 : 입수 수단별 대시보드
- 세계의 편두통 치료제 시장 : 입수 수단별 변동 분석
- 세계의 편두통 치료제 시장 : 입수 수단별(수익 베이스)
- 처방약
- 시판약(OTC)
제9장 편두통 치료제 시장 : 유형별 추정 및 동향 분석(치료제별, 치료 클래스별 및 투여 경로별)
- 지역 대시보드
- 시장 규모, 예측 및 동향 분석(2018-2030년)
- 북미
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
제10장 경쟁 구도
- 주요 시장 진출 기업에 의한 최근의 동향 및 영향 분석
- 기업 및 경쟁의 분류
- 벤더 상황
- 주요 리셀러 및 채널 파트너 목록
- Key customers
- Key company market share analysis, 2023
- AbbVie Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Eli Lilly and Company
- Pfizer Inc.
- Bausch Health Companies Inc.
- Gensco Pharma
- Impel Pharmaceuticals Inc.
- Currax Pharmaceuticals LLC.
- Lundbeck
AJY
영문 목차
Migraine Drugs Market Growth & Trends:
The global migraine drugs market size is expected to reach USD 13.34 billion by 2030, registering a CAGR of 10.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.
Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.
Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.
Migraine Drugs Market Report Highlights:
- Based on treatment, the preventive segment led the market with the largest revenue share of 62.03% in 2024. The Acute segment held the second largest market revenue share in 2024.
- Based on the therapeutic class, the CGRP monoclonal antibodies segment led the market with the largest revenue share of 56.68% in 2024. The CGRP small molecule antagonist diagnostics segment is anticipated to grow at the fastest CAGR over the forecast period.
- Based on the route of administration, the injectable segment led the market with the largest revenue share of 69.48% in 2024. The oral segment is projected to witness a significant CAGR over the forecast period.
- Based on age group, the adult segment led the market with the largest revenue share of 52.92% in 2024 and is anticipated to grow at a significant CAGR over the forecast period. The geriatric segment is anticipated to grow at a significant CAGR over the forecast period.
- Based on availability, the prescription drugs segment led the market with the largest revenue share of 62.38% in 2024 and is anticipated to grow at a significant CAGR over the forecast period.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Treatment
- 1.2.2. Therapeutic Class
- 1.2.3. Route of Administration
- 1.2.4. Age Group
- 1.2.5. Availability
- 1.2.6. Regional scope
- 1.2.7. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Treatment and Therapeutic Class outlook
- 2.2.2. Route of Administration outlook
- 2.2.3. Age Group and Availability outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Migraine Drugs Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of migraines
- 3.2.1.2. Advancements in drug development
- 3.2.1.3. Growing awareness and diagnosis
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of development
- 3.2.2.2. Regulatory challenges for new drug approvals
- 3.3. Migraine Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.4. Pricing Analysis
- 3.5. Pipeline Analysis, by Phase
Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis
- 4.1. Global Migraine Drugs Market: Treatment Dashboard
- 4.2. Global Migraine Drugs Market: Treatment Movement Analysis
- 4.3. Global Migraine Drugs Market by Treatment, Revenue
- 4.4. Acute
- 4.4.1. Acute market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Preventive
- 4.5.1. Preventive market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis
- 5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
- 5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
- 5.3. Global Migraine Drugs Market by Therapeutic Class, Revenue
- 5.4. CGRP monoclonal antibodies
- 5.4.1. CGRP monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. CGRP small molecule antagonists
- 5.5.1. CGRP small molecule antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Acetylcholine inhibitors/ neurotoxins
- 5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Triptans
- 5.7.1. Triptans market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.8. Ditans
- 5.8.1. Ditans market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.9. Ergot alkaloids
- 5.9.1. Ergot alkaloids market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.10. NSAIDs
- 5.10.1. NSAIDs market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.11. Others
- 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis
- 6.1. Global Migraine Drugs Market: Route of Administration Dashboard
- 6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
- 6.3. Global Migraine Drugs Market by Route of Administration, Revenue
- 6.4. Oral
- 6.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Injectable
- 6.5.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis
- 7.1. Global Migraine Drugs Market: Age Group Dashboard
- 7.2. Global Migraine Drugs Market: Age Group Movement Analysis
- 7.3. Global Migraine Drugs Market by Age Group, Revenue
- 7.4. Pediatric
- 7.4.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5. Adult
- 7.5.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6. Geriatric
- 7.6.1. Geriatric market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis
- 8.1. Global Migraine Drugs Market: Availability Dashboard
- 8.2. Global Migraine Drugs Market: Availability Movement Analysis
- 8.3. Global Migraine Drugs Market by Availability, Revenue
- 8.4. Prescription Drugs
- 8.4.1. Prescription Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.5. Over-the-Counter (OTC) Drugs
- 8.5.1. Over-the-Counter (OTC) Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
- 9.1. Regional Dashboard
- 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 9.3. North America
- 9.3.1. U.S.
- 9.3.1.1. Key country dynamics
- 9.3.1.2. Regulatory framework/ reimbursement structure
- 9.3.1.3. Competitive scenario
- 9.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.3.2. Canada
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework/ reimbursement structure
- 9.3.2.3. Competitive scenario
- 9.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.3.3. Mexico
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework/ reimbursement structure
- 9.3.3.3. Competitive scenario
- 9.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4. Europe
- 9.4.1. UK
- 9.4.1.1. Key country dynamics
- 9.4.1.2. Regulatory framework/ reimbursement structure
- 9.4.1.3. Competitive scenario
- 9.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.2. Germany
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework/ reimbursement structure
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.3. France
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework/ reimbursement structure
- 9.4.3.3. Competitive scenario
- 9.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.4. Italy
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework/ reimbursement structure
- 9.4.4.3. Competitive scenario
- 9.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.5. Spain
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework/ reimbursement structure
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.6. Norway
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework/ reimbursement structure
- 9.4.6.3. Competitive scenario
- 9.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework/ reimbursement structure
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.8. Denmark
- 9.4.8.1. Key country dynamics
- 9.4.8.2. Regulatory framework/ reimbursement structure
- 9.4.8.3. Competitive scenario
- 9.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Japan
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.2. China
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.3. India
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.4. Australia
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework/ reimbursement structure
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.5. South Korea
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Regulatory framework/ reimbursement structure
- 9.5.5.3. Competitive scenario
- 9.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key country dynamics
- 9.5.6.2. Regulatory framework/ reimbursement structure
- 9.5.6.3. Competitive scenario
- 9.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6. Latin America
- 9.6.1. Brazil
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.2. Argentina
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7. Middle East & Africa
- 9.7.1. South Africa
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.4. Kuwait
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Company/Competition Categorization
- 10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company market share analysis, 2023
- 10.3.4. AbbVie Inc.
- 10.3.4.1. Company overview
- 10.3.4.2. Financial performance
- 10.3.4.3. Product benchmarking
- 10.3.4.4. Strategic initiatives
- 10.3.5. Amgen Inc.
- 10.3.5.1. Company overview
- 10.3.5.2. Financial performance
- 10.3.5.3. Product benchmarking
- 10.3.5.4. Strategic initiatives
- 10.3.6. Teva Pharmaceutical Industries Ltd.
- 10.3.6.1. Company overview
- 10.3.6.2. Financial performance
- 10.3.6.3. Product benchmarking
- 10.3.6.4. Strategic initiatives
- 10.3.7. GSK plc
- 10.3.7.1. Company overview
- 10.3.7.2. Financial performance
- 10.3.7.3. Product benchmarking
- 10.3.7.4. Strategic initiatives
- 10.3.8. Eli Lilly and Company
- 10.3.8.1. Company overview
- 10.3.8.2. Financial performance
- 10.3.8.3. Product benchmarking
- 10.3.8.4. Strategic initiatives
- 10.3.9. Pfizer Inc.
- 10.3.9.1. Company overview
- 10.3.9.2. Financial performance
- 10.3.9.3. Product benchmarking
- 10.3.9.4. Strategic initiatives
- 10.3.10. Bausch Health Companies Inc.
- 10.3.10.1. Company overview
- 10.3.10.2. Financial performance
- 10.3.10.3. Product benchmarking
- 10.3.10.4. Strategic initiatives
- 10.3.11. Gensco Pharma
- 10.3.11.1. Company overview
- 10.3.11.2. Financial performance
- 10.3.11.3. Product benchmarking
- 10.3.11.4. Strategic initiatives
- 10.3.12. Impel Pharmaceuticals Inc.
- 10.3.12.1. Company overview
- 10.3.12.2. Financial performance
- 10.3.12.3. Product benchmarking
- 10.3.12.4. Strategic initiatives
- 10.3.13. Currax Pharmaceuticals LLC.
- 10.3.13.1. Company overview
- 10.3.13.2. Financial performance
- 10.3.13.3. Product benchmarking
- 10.3.13.4. Strategic initiatives
- 10.3.14. Lundbeck
- 10.3.14.1. Company overview
- 10.3.14.2. Financial performance
- 10.3.14.3. Product benchmarking
- 10.3.14.4. Strategic initiatives
관련자료
